Latest Insider Transactions at Gelesis Holdings, Inc. (GLS)
This section provides a real-time view of insider transactions for Gelesis Holdings, Inc. (GLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GELESIS HOLDINGS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GELESIS HOLDINGS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2022
|
Raju S Kucherlapati |
BUY
Open market or private purchase
|
Direct |
92,000
+32.59%
|
$0
$0.45 P/Share
|
|
Nov 18
2022
|
Raju S Kucherlapati |
BUY
Open market or private purchase
|
Direct |
8,000
+7.53%
|
$0
$0.39 P/Share
|
|
Jun 15
2022
|
Raju S Kucherlapati |
BUY
Open market or private purchase
|
Direct |
24,625
+21.43%
|
$24,625
$1.95 P/Share
|
|
Jun 08
2022
|
Elaine Chiquette Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,500
+23.43%
|
-
|
|
May 06
2022
|
Alison Bauerlein Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,095
+50.0%
|
-
|
|
May 06
2022
|
Kathryn Cavanaugh Director |
BUY
Grant, award, or other acquisition
|
Direct |
48,814
+44.19%
|
-
|
|
May 06
2022
|
David Abraham General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
256,437
+48.84%
|
-
|
|
May 06
2022
|
Elaine Chiquette Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
182,579
+47.41%
|
-
|
|
May 06
2022
|
Clayton Christopher Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,270
+8.8%
|
-
|
|
May 06
2022
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,832
+50.0%
|
-
|
|
May 06
2022
|
Raju S Kucherlapati |
BUY
Grant, award, or other acquisition
|
Direct |
50,639
+43.55%
|
-
|
|
May 06
2022
|
Harry L. Leider Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
314,090
+46.58%
|
-
|
|
May 06
2022
|
Elliot Maltz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
431,975
+48.02%
|
-
|
|
May 06
2022
|
David A. Pass Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
483,219
+46.9%
|
-
|
|
May 06
2022
|
Dominic Perks Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,270
+50.0%
|
-
|
|
May 06
2022
|
Alessandro Sannino Lead Project Scientist |
BUY
Grant, award, or other acquisition
|
Direct |
68,966
+24.98%
|
-
|
|
May 06
2022
|
Jane Wildman Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,182
+50.0%
|
-
|
|
May 06
2022
|
Yishai Zohar President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
960,893
+13.23%
|
-
|
|
Jan 14
2022
|
Raju S Kucherlapati |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$90,000
$6.67 P/Share
|
|
Jan 13
2022
|
Kathryn Cavanaugh Director |
BUY
Other acquisition or disposition
|
Direct |
12,825
+50.0%
|
-
|
|
Jan 13
2022
|
Kathryn Cavanaugh Director |
SELL
Other acquisition or disposition
|
Direct |
12,825
-100.0%
|
-
|
|
Jan 13
2022
|
Kathryn Cavanaugh Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,825
+50.0%
|
-
|